Skip to main content Skip to search Skip to main navigation

ICH: Press Release ICH-Assembly Meeting

The ICH published a press release on June 20, regarding a face-to-face meeting on June 12 and 13, 2023, in Vancouver, Canada. Meetings of 14 working groups, the ICH Management Committee and the MedDRA Management Committee were also held during that time.

New Areas of ICH Harmonisation

Three new areas of harmonisation were defined at the meeting:

  • “General Considerations for Patient Preference Studies” – Efficacy guideline with considerations for a systematic approach to planning, conducting, analyzing, and processing patient preference studies when they contain important advanced information for evaluating products or inform drug development and related decisions.
  • “Nonclinical Safety Studies for Oligonucleotide-based Therapeutics” – Safety Guideline that communicates regulatory requirements for non-clinical safety evaluations of various oligonucleotide-based treatment options through general understanding.
  • “Bioequivalence for Modified-Release Products” – Multidisciplinary Guideline that represents an important step towards the harmonisation of bioequivalence standards for more complex dosage forms. The harmonised elements of the M13 Guideline series are transferable.

In a later step, the starting timeframe will be defined.

Additional results of the meeting are:

  • The formation of a new ICH “Cell and Gene Therapies” Discussion Group (CGTDG), providing a technical communication forum for issues related to ICH harmonisation efforts in the area of CGT products.
  • A new ICH Reflection Paper for the “International Harmonisation of Real-World Evidence Terminology and Convergence of General Principles Regarding Planning and Reporting of Studies Using Real-World Data, with a Focus on Effectiveness of Medicines”.
  • They noted significant milestones since the last ICH meeting, for example the adoptation of the revised ICH Q9 (R1) Guideline on “Quality Risk Management” in January 2023.

The press release also states that the African Authority EDA (Egypt) has joined ICH as a Member and NAFDAC (Nigeria) as an ICH Observer.


Source

ICH: Press Release

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ANVISA: Expands Recognition of Foreign GMP Authorities

ANVISA: Expands Recognition of Foreign GMP Authorities

Brazilian health authority ANVISA has updated the requirements for the recognition of Equivalent Foreign Regulatory Authorities (AREE) and the administrative procedures for Good Manufacturing Practice (GMP) certification (CBPF) through Normative Instruction IN 451/2026. The aim is to streamline and accelerate regulatory processes.
Read more
EDQM: Guidance on Reporting on Disappearances of Medicinal Products

EDQM: Guidance on Reporting on Disappearances of Medicinal Products

The EDQM has published guidance supporting the implementation of Recommendation CM/Rec(2024)3 on reporting medicinal products that disappear from the legal supply chain due to theft, loss or diversion. The initiative follows a European survey that identified shortcomings in reporting and co-ordination of such incidents.

Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
Previous
Next